Latest News

The partnership will bring select consultant vascular and endovascular surgeons from Sir Ganga Ram Hospital’s IVES to C37’s Dubai facility.

The new unit employs advanced systems that optimize water usage during dialysis treatments, reducing waste without affecting treatment efficacy.

The site can produce up to 40 CGMP batches annually, supporting parallel processing for multiple client programs and ensuring reliable supply chains.

The facility will house sophisticated equipment, including liquid-phase peptide synthesis reactors ranging from 250 to 3,000 liters and solid-phase peptide synthesis reactors up to 500 liters.

The platform integrates medical devices and health information systems, creating a connected data thread with central monitoring and surveillance workflows that support clinical decision-making across encounters and over time.

The ministry plans to enable electronic information exchange between facilities, which will streamline medical services and reduce administrative burdens on both healthcare providers and patients seeking treatment.

Abdallah previously served as Chief Investment Officer and has maintained close involvement with Cambridge Health Group for several years.

This arrangement strengthens an existing partnership between the two pharmaceutical giants, who already collaborate on manufacturing the mpox vaccine.

This latest commitment builds on a previous 7 billion yen (USD44 million) investment between 2022 and 2025, which funded automated device-sorting machines, enhancements to the quality testing lab, a new factory building, and an additional packaging line.

The management has allocated the funds specifically to address critical equipment shortages that currently limit the hospital’s service delivery capacity.